摘要
全球非酒精性脂肪肝(NAFLD)的患病率增加,成为现代全球医疗体系的一个挑战。脂毒性过程以促进伤口愈合过程(纤维化)的氧化应激及紧随其后的突发免疫反应为特征,这最终会导致硬化和并发症的发展。目前没有一种有效的药物治疗被一致认同。因此,我们需要有效治疗的化合物。水飞蓟素,乳蓟的主要活性成分,因其抗氧化、抗炎和抗纤维化的特性而成为候选药物。虽然我们通过实验模型获得了大量数据,但临床环境下的证据仍不足以决定其向临床转化。本文诣在批判性地综述水飞蓟素的不同剂型在多种实验和临床环境中的应用并指导未来研究。
关键词: 细胞凋亡,纤维化,炎症,胰岛素抵抗氧化应激,水飞蓟素,脂肪变性。
Current Medicinal Chemistry
Title:The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular)
Volume: 22 Issue: 25
Author(s): Natalia Rosso, Veronica Marin, Antonio Giordani, Stefano Persiani, Federica Sala, Lucio Cavicchioli, Lucio C. Rovati and Claudio Tiribelli
Affiliation:
关键词: 细胞凋亡,纤维化,炎症,胰岛素抵抗氧化应激,水飞蓟素,脂肪变性。
摘要: The increasing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) worldwide is becoming a challenge for the modern global care system. The lipotoxic process is characterized by an oxidative stress followed by a burst of the inflammatory response, prompting the wound healing process (fibrosis), which can ultimately lead to the development of cirrhosis and the subsequent complications. There is no consensus concerning an effective pharmacological treatment. Therefore, there is a need for effective therapeutic compounds. Silibinin the major active compound of Milk Thistle may be a potential candidate mainly due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties. In spite of the large number of data obtained in experimental models, the translation of the evidence in clinical setting is far to be conclusive. The aim of this paper is to critically review the aspects of the use of the different formulations of Silibinin in several experimental and clinical settings and to provide hints on the needed future studies.
Export Options
About this article
Cite this article as:
Natalia Rosso, Veronica Marin, Antonio Giordani, Stefano Persiani, Federica Sala, Lucio Cavicchioli, Lucio C. Rovati and Claudio Tiribelli , The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular), Current Medicinal Chemistry 2015; 22 (25) . https://dx.doi.org/10.2174/0929867322666150729114235
DOI https://dx.doi.org/10.2174/0929867322666150729114235 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity
Mini-Reviews in Medicinal Chemistry Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Recent Patents on the Development of c-Met Kinase Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Gene Delivery for Cancer Therapy
Current Drug Delivery Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Current Drug Targets Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry CpG Island Methylation in Precursors of Gastrointestinal Malignancies
Current Molecular Medicine Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
Current Medicinal Chemistry Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Regenerative Medicine Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target
Mini-Reviews in Medicinal Chemistry Novel Hexahydropyridoindole Derivative as Prospective Agent Against Oxidative Damage in Pancreatic βCells
Medicinal Chemistry